# Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

> **NCT02517502** · EARLY_PHASE1 · COMPLETED · sponsor: **Carol Fabian, MD** · enrollment: 24 (actual)

## Conditions studied

- Cognitive Dysfunction

## Interventions

- **DRUG:** DHA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02517502
- **Lead sponsor:** Carol Fabian, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-09
- **Final completion:** 2019-05-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517502, "Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02517502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*